BEVERLY ILTIS: Open Payments
NPI 1326015074 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,303 in 80 payments from 18 companies in 2025. Trend: 2023 $1,400 · 2024 $1,063 · 2025 $1,303
Food & beverage: $1,303
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 19 | $266 |
| ABBVIE INC. | 17 | $234 |
| Abbott Laboratories | 3 | $164 |
| GlaxoSmithKline, LLC. | 17 | $151 |
| Corcept Therapeutics | 4 | $130 |
| Lilly USA, LLC | 4 | $77 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Novartis Pharmaceuticals Corporation | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 2 | $34 |
| Merck Sharp & Dohme LLC | 2 | $31 |
Products named: Rybelsus, TRELEGY ELLIPTA, Korlym, JOT DX, VRAYLAR, UBRELVY, QULIPTA, Wegovy.
Industry payments across TX — which companies pay providers there.
